Relevant bibliographies by topics / Ca 19

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Ca 19'

Author: Grafiati
Published: 4 June 2021
Last updated: 6 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Ca 19.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Ca 19"

1

Gaillard, O. "CA 19-9." Immuno-analyse & Biologie Spécialisée 16, no. 4 (July 2001): 244–45. http://dx.doi.org/10.1016/s0923-2532(01)80017-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Troalen, Frédéric. "CA 19-9." EMC - Biologie Médicale 1, no. 1 (January 2006): 1–4. http://dx.doi.org/10.1016/s2211-9698(06)76034-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fiala, Ludek, Petr Bob, and Jiri Raboch. "Oncological markers CA-125, CA 19-9 and endometriosis." Medicine 97, no. 51 (December 2018): e13759. http://dx.doi.org/10.1097/md.0000000000013759.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Graulet, AM. "Informations réactifs : CA 19-9." Immuno-analyse & Biologie Spécialisée 16, no. 1 (January 2001): 59–64. http://dx.doi.org/10.1016/s0923-2532(01)80011-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Passek, K., M. H. Bendels, D. Ohlendorf, E. Wanke, G. M. Oremek, and D. A. Groneberg. "Der Tumormarker CA 19-9." Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie 67, no. 6 (August 30, 2017): 327–29. http://dx.doi.org/10.1007/s40664-017-0211-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wirquin, V. "Informations réactifs: Marqueurs tumoraux: CA 19-9, CA 125, CA 15-3, CA 50, CA 72-4." Immuno-analyse & Biologie Spécialisée 11, no. 3 (January 1996): 208–11. http://dx.doi.org/10.1016/0923-2532(96)83018-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hoffmann, L., S. Müller-Hagen, G. Franz, R. Klapdor, and M. Dietel. "Die Tumormarker CA 125, CA 19-9, CA 15-3 und CEA beim Ovarialkarzinom." Archives of Gynecology and Obstetrics 242, no. 1-4 (March 1987): 371–72. http://dx.doi.org/10.1007/bf01783165.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tekin, Oğuz. "Hypothyroidism-Related CA 19-9 Elevation." Mayo Clinic Proceedings 77, no. 4 (April 2002): 398. http://dx.doi.org/10.4065/77.4.398.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ritts, Roy E., and Henry A. Pitt. "CA 19-9 in Pancreatic Cancer." Surgical Oncology Clinics of North America 7, no. 1 (January 1998): 93–101. http://dx.doi.org/10.1016/s1055-3207(18)30286-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

ATIQUZZAMAN, B. "High CA 19?9 in choledocholithiasis." American Journal of Gastroenterology 98, no. 9 (September 2003): S180. http://dx.doi.org/10.1016/s0002-9270(03)01306-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Ca 19"

1

Zulj, Jelena. "Verifiering av metod för analys av tumörmarkörerna CA 125, CA 15-3 och CA 19-9 på Roche Cobas e411." Thesis, Linnéuniversitetet, Institutionen för kemi och biomedicin (KOB), 2014. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-37279.

Full text
Abstract:
Tumörmarkörer är substanser som frisätts i kroppsvätskor från cancerceller. Markörerna används inom sjukvården för att upptäcka och följa upp maligna sjukdomar med analyser av markörerna i serum/plasma. Tre av dessa är cancerantigenerna CA 125, CA 15-3 och CA 19-9. Syftet med studien var att verifiera analysmetoden för tumörmarkörerna CA 125, CA 15-3 och CA 19-9 på två Roche Cobas e411 instrument (instrument 1 och 2) inför införandet av dessa vid avdelningen för klinisk kemi och transfusionsmedicin, Lnadstinget Kalmar län. De av företaget rekommenderade cut-off värdena på Roche Cobas e411 (Roche Diagnostics) är för CA 125 <35 kU/l, för CA 15-3 ≤25 kU/l och för CA 19-9 <27 kU/l. Precisionen beräknades med hjälp av statistiska metoder genom analys av den mellanliggande precisionen (mätning av två kontrollnivåer under 5 dagar) och repeterbarheten (analys av två kontrollnivåer i en serie). En korrelationsstudie gjordes med patientprover som erhölls från Aleris Medilab (Abbot Architect i System). Den mellanliggande precisionenn resulterade i högre variationskoefficientvärden (CV %) för samtliga tre markörer i förhållande till ett åsatt CV från Roche Diagnostics. CV värdet skilde även mellan de två Roche Cobas e411 instrumenten. Repeterbarheten bedömdes vara acceptabel för samtliga tre markörer. Korrelationsstudien visade en skillnad i de uppmätta värdena mellan Roche Cobas e411 och Abbot Architect för samtliga tre markörer. Då Roche Cobas e411 tenderade att ge högre uppmätta värden (kU/l) (54 av 85 gånger). Samstämmigheten mellan metoderna var bra då det endast var två prover vid analys av CA 15-3 och två prover vid analys av CA 19-9 som var på skilda sidor om cut-off värdet. Sammanfattningsvis visade studien att den mellanliggande precisisonen (CV-värdet) för alla tre markörerna var högre än Roche Diagnostics angivna CV värde. Olika CV värden erhölls med Roche Cobas e411 jämfört med Abbot Architect. Olika CV värden erhölls också med instrument 1 jämfört med instrument 2. Precisionen anses vara tillräckligt god för införandet av metoderna i rutinbruk.
APA, Harvard, Vancouver, ISO, and other styles
2

OTTO, JOSIANE. "Elevation du ca 19-9 dans les fibroses pulmonaires idiopathiques." Nice, 1992. http://www.theses.fr/1992NICE6575.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dericioglu, Mete [Verfasser]. "Die prognostische Relevanz der Tumormarker AFP, CEA, CA 19-9 und CA 125 vor Lebertransplantationen / Mete Dericioglu." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2020. http://d-nb.info/1218077867/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kritly, Taric. "Etude comparative des marqueurs tumoraux seriques ace, nse, ca 19. 9, ca 125, ca 50 dans les tumeurs solides de l'adulte : a propos de 207 observations." Reims, 1988. http://www.theses.fr/1988REIMM035.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hartmann, Marie-Thérèse. "Interet du scc ta-4 dans le cancer epidermoide de l'oesophage par rapport a l'ace - ca 19-9 - ca 125." Nice, 1991. http://www.theses.fr/1991NICE6508.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Soares, Andrey Coatrini. "Filmes nanoestruturados aplicados em biossensores para detecção precoce de câncer de pâncreas." Universidade de São Paulo, 2017. http://www.teses.usp.br/teses/disponiveis/18/18158/tde-30032017-080111/.

Full text
Abstract:
A necessidade de dispositivos analíticos para detecção precoce de câncer tem motivado pesquisas em nanomateriais de baixo custo, com busca de sinergia para obter alta sensibilidade e seletividade em biossensores. Neste trabalho, o ácido 11-mercaptoundecanóico, o polímero natural quitosana e a proteína concanavalina A (Con A) foram usados como plataforma para imobilizar anticorpos anti-CA 19-9 e construir biossensores para detecção de câncer de pâncreas. Esses biossensores foram produzidos com uma matriz de filmes automontados por adsorção química (self-assembled monolayers, SAM) e por adsorção física (layer-by-layer, LbL). A caracterização com técnicas espectroscópicas e gravimétricas permitiu selecionar as arquiteturas com quitosana/ Con A 2:1 (sensor A), quitosana/ Con A 1:1 (sensor B) e 11-MUA (sensor E), como sendo mais favoráveis à imobilização do anticorpo anti-CA 19-9. Usando os biossensores com espectroscopia de impedância foi possível detectar baixas concentrações do biomarcador CA 19-9, com limites de detecção entre 0,17-0,69 U/mL, 0,31-0,91 U/mL e 0,56-0,91 U/mL para os sensores A, B e E, respectivamente. Esses limites são suficientes para detectar câncer de pâncreas nos estágios iniciais. A seletividade dos dispositivos foi inferida em uma série de experimentos de controle com amostras de células SW 620 e HT-29, ácido úrico, ácido ascórbico, glicose, manose, sérum e antígeno p24, indicando ausência de interferência não específica ao biomarcador. O uso de técnicas de visualização de informação permitiu facilmente distinguir essas amostras, classificando-as de acordo com a concentração do biomarcador em um mapa. Permitiu também quantificar a seletividade dos biossensores através do coeficiente de silhueta, com valores 0,853, 0,861 e 0,897 para os sensores A, B e E, respectivamente. Essa especificidade dos biossensores foi confirmada por medidas de PM-IRRAS, através das bandas de amida I e II em 1566 cm-1 e 1650 cm-1, indicando a interação específica entre anticorpo e antígeno, que pode ser modelada com uma isoterma de Langmuir-Freundlich. Quando a matriz de quitosana/ Con A foi substituída por um filme monocamada ou quando se empregou um biomarcador de maior peso molecular, a adsorção do biomarcador foi explicada por uma combinação de dois processos de Langmuir-Freundlich. Conclui-se que os biossensores de baixo custo podem ser eficientes para diagnóstico e prognóstico, e serem implementados na rede nacional de saúde com disseminação da tecnologia.
The need of analytical devices to detect cancer at early stages has motivated research into nanomaterials where synergy is sought to achieve high sensitivity and selectivity in biosensors. In this work, 11-mercaptoundecanoic acid, the polymer chitosan and the protein concanavalin A (Con A) were used as a platform to immobilize the anti-CA 19-9 antibody using the self-assembled monolayer (SAM) and the layer-by-layer (LbL) techniques. The characterization with spectroscopic and gravimetric techniques allowed us to select the architectures with chitosan/Con A 2:1 (Sensor A), chitosan/Con A 1:1 (Sensor B) and 11 MUA (Sensor E) as optimized for immobilization of anti-CA 19-9 antibodies. Using impedance spectroscopy, the biosensors were capable of detecting low concentrations of CA 19-9 biomarker, with limit of detection in the range 0.17-0.69 U/mL, 0.31-0.91 U/mL and 0.56-0.91 U/mL for sensors A, B and E, respectively. These limits are sufficient to detect pancreatic cancer at early stages. The selectivity of the biosensors was inferred in a series of control experiments with cell samples SW-620 and HT-29, uric acid, ascorbic acid, glucose, mannose, serum and p24 antigen, indicating the absence of non-specific interference. With information visualization techniques, these samples could be easily distinguished in a visual map, and be classified according to their content of CA 19-9. Furthermore, the selectivity could be quantified through the silhouette coefficient, with values 0.853, 0.861 and 0.897 for sensors A, B and E, respectively. This biosensor specificity was confirmed with PM-IRRAS measurements by monitoring the amide I and II bands at 1566 cm-1 and 1650 cm-1. The specific interaction between antibody and antigen was modeled with a Langmuir-Freundlich isotherm. When the chitosan/Con A matrix was replaced by a SAM monolayer or if a larger biomarker was employed, adsorption was explained by a combination of two Langmuir-Freundlich processes. In conclusion, low cost biosensors may be effective for diagnostics and prognostics, and may be further implemented in the Brazilian national health system with technology transfer.
APA, Harvard, Vancouver, ISO, and other styles
7

BILDSTEIN, LAURE. "Evaluation quantitative des mucines conjonctivales par dosage du ca 19-9 sur empreintes." Dijon, 1994. http://www.theses.fr/1994DIJOM061.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Dumitra, Sinziana. "CA 19-9 and the McGill Brisbane Symptom Score: predictors of pancreatic cancer survival." Thesis, McGill University, 2013. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=116938.

Full text
Abstract:
Background: Clinical tools that predict pancreatic adenocarcinoma (PAC) survival to help tailor treatments are lacking. Our surgical group has developed a clinical score, the McGill Brisbane Symptom Score (MBSS) that predicts PAC survival in resectable and non-resectable PAC. CA 19-9, a biomarker used in the diagnosis of PAC, has demonstrated increased potential as a predictor of PAC survival.Objectives: To determine if the Pancreatic Adenocarcinoma Survival Score (PACSS), a combined score of the CA 19-9-to-bilirubin ratio and the MBSS, better predicts survival in patients with resectable pancreatic cancer compared to the MBSS alone. Methods: A retrospective chart review of 122 patients treated at the McGill University Health Center (MUHC) and the University Hospital Zurich (UHZ) was undertaken. For all patients we calculated the MBSS and the PACSS at the time of diagnosis and ascertained the 2-year survival. Results: Both the MBSS and the PACSS were strong predictors of survival with Hazard Ratios (HR) of 2.58 (95%CI 1.35-4.91) and 3.06 (95%CI 1.64 - 5.70), respectively. Adding the patient age and sex, two other variables available at the time of diagnosis did not significantly improve the predictive ability of the models containing either the PACSS or the MBSS. Conclusions: Adding the CA 19-9-to-bilirubin ratio to the MBSS to form the PACSS may improve the predictive ability when compared to the MBSS alone. However the overlap in the 95% confidence intervals does not allow us to conclude that the difference is statistically significant.
Mise en contexte : Il existe peu d'outils cliniques permettant de prédire la survie des patients souffrant d'adénocarcinome du pancréas (ACP). Notre groupe a développé un score clinique, le McGill Brisbane Symptom Score (MBSS) permettant de prédire la survie chez les patients souffrant d'ACP resequable et non resequable. Objectifs Cette étude a pour but de déterminer si un score combinant le ratio Ca 19-9 sur bilirubine et le MBSS soit le the Pancreatic Adenocarcinoma Survival Score (PACSS), prédit mieux le survie chez les patients avec un ACP resequable compare uniquement au MBSS. Méthodes Une revue de dossiers rétrospective chez 122 patients traite au McGill University Health Center (MUHC) et au University Hospital Zurich (UHZ) fut entreprise. Pou tout les patients on a calcule le MBSS et le PACSS au moment du diagnostic et avons déterminé la survie a 2 ans. Résultats Le MBSS est un bon prédicteur de survie avec un (HR) de 2.58 (95%IC 1.35-4.91). Le PACSS fut le plus puissant prédicteur indépendant de survie avec un HR of 3.06 (95%IC 1.64 - 5.70). En ajoutant l'âge et le sexe, le pouvoir prédictif des deux modèles n'est pas amélioré. Conclusions En ajoutant le ratio Ca 19-9 sur bilirubine au MBSS pour former le PACSS peut améliorer le pouvoir prédictif compare au MBSS. Cependant du a une superposition des intervalles de confiance, nous ne pouvons conclure sur la significance statistique de cette différence.
APA, Harvard, Vancouver, ISO, and other styles
9

Haas, Michael. "Der prognostische Stellenwert des Tumormarkers CA 19-9 und weiterer laborchemischer Parameter beim fortgeschrittenen Pankreaskarzinom." Diss., lmu, 2011. http://nbn-resolving.de/urn:nbn:de:bvb:19-137474.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

BELJIO, KATIA. "Elevation du ca 19. 9 au cours des rhumatismes inflammatoires dysimmunitaires : a propos de six observations." Toulouse 3, 1992. http://www.theses.fr/1992TOU31041.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Ca 19"

1

Internet, Librarian Conference (1st 1997 Monterey Calif ). Internet librarian '97: Proceedings 1997, Monterey, CA, November 17-19, 1997. Medford, N.J: Information Today, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Photonics in Switching (2007 San Francisco, Calif.). 2007 Photonics in Switching: San Francisco, CA, 19-22 August 2007. New York City, NY: IEEE, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Photonics in Switching (2007 San Francisco, Calif.). 2007 Photonics in Switching: San Francisco, CA, 19-22 August 2007. New York City, NY: IEEE, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Staat und Kirche im deutschen Naturrecht: Das natürliche Kirchenrecht des 18. und 19. Jahrhunderts (ca. 1680 bis ca. 1850). Tübingen: Mohr Siebeck, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Biological Sciences Symposium (1997 San Francisco, Calif.). 1997 Biological sciences symposium: October 19-23, 1997 San Francisco Marriott, San Francisco, CA. Atlanta, GA: TAPPI Press, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

IEEE/SEMI International Semiconductor Manufacturing Science Symposium. (5th 1993 San Francisco, Calif.). IEEE/SEMI International Semiconductor Manufacturing Science Symposium: July 19-20, 1993, San Francisco, CA USA. New York, N.Y: Institute of Electrical and Electronics Engineers, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Design Automation Conference (35th 1998 San Francisco, Calif.). Proceedings 1998, Design Automation Conference: 35th anniversary : Moscone Center, San Francisco, CA, June 15-19, 1998. New York, NY: Available from ACM Order Dept., 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Computer Animation (15th 2002 Geneva, Switzerland). Computer Animation 2001: Proceedings of Computer Animation 2002 (CA 2002) : 19-21 June, 2002, Geneva, Switzerland. Los Alamitos, Calif: IEEE Computer Society Press, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

International, Verilog HDL Conference (1st 1998 Santa Clara CA). International Verilog HDL Conference and VHDL International Users Forum: Proceedings, March 16-19, 1998, Santa Clara, CA. Los Alamitos, CA: IEEE Conmputer Society, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Association, USENIX, ed. Proceedings of the Eighth Systems Administration Conference (LISA VIII), September 19-23, 1994, San Diego, CA, USA. Berkeley, CA: USENIX Association, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Ca 19"

1

Ward, Tony Milford. "Carbohydrate Antigen CA 19-9." In Proteins and Tumour Markers May 1995, 956–63. Dordrecht: Springer Netherlands, 1995. http://dx.doi.org/10.1007/978-94-011-0681-8_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Haase, Eric. "Entwicklung der Organisationsstrukturen ab ca. 1960." In Organisationskonzepte im 19. und 20. Jahrhundert, 121–79. Wiesbaden: Deutscher Universitätsverlag, 1995. http://dx.doi.org/10.1007/978-3-322-95450-3_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Scarà, Salvatore, Patrizia Bottoni, and Roberto Scatena. "CA 19-9: Biochemical and Clinical Aspects." In Advances in Cancer Biomarkers, 247–60. Dordrecht: Springer Netherlands, 2015. http://dx.doi.org/10.1007/978-94-017-7215-0_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lamerz, Rolf. "CA 19–9, GICA (Gastrointestinal Cancer Antigen)." In Serological Cancer Markers, 309–39. Totowa, NJ: Humana Press, 1992. http://dx.doi.org/10.1007/978-1-4612-0401-5_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Göhring, U. G., F. Weber, A. Scharl, and A. Bolte. "Vorkommen der tumorassoziierten Antigene CA 50 und CA 19-9 in Endometriumkarzinomen." In Gynäkologie und Geburtshilfe 1992, 993–95. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-77857-5_382.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Haase, Eric. "Entwicklung der Organisationsstrukturen ca. 1915 bis 1975: Die Spartenorganisation." In Organisationskonzepte im 19. und 20. Jahrhundert, 101–19. Wiesbaden: Deutscher Universitätsverlag, 1995. http://dx.doi.org/10.1007/978-3-322-95450-3_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Frieß, H., M. Büchler, B. Auerbach, A. Weber, K. Hammer, and H. G. Beger. "CA 494: Ein neuer Serum-Tumormarker mit besserer Spezifität als CA 19-9." In Chirurgisches Forum ’92 für experimentelle und klinische Forschung, 15–19. Berlin, Heidelberg: Springer Berlin Heidelberg, 1992. http://dx.doi.org/10.1007/978-3-642-77389-1_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Haase, Eric. "Entwicklung der Organisationsstrukturen bis ca. 1920: Die Herausbildung der Funktionalen Organisation." In Organisationskonzepte im 19. und 20. Jahrhundert, 34–71. Wiesbaden: Deutscher Universitätsverlag, 1995. http://dx.doi.org/10.1007/978-3-322-95450-3_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Cirkel, U., H. Ochs, and H. P. G. Schneider. "Konzentration der Tumormarker CA 125, CA 19–9, CA 15–3, CEA unter einer LHRH-Analog-Therapie wegen Endometriose." In Gynäkologie und Geburtshilfe 1990, 1022–23. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-76124-9_531.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Krishna, Kavya, and Tanios Bekaii-Saab. "CA 19-9 as a Serum Biomarker in Cancer." In Biomarkers in Cancer, 179–201. Dordrecht: Springer Netherlands, 2015. http://dx.doi.org/10.1007/978-94-007-7681-4_17.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Ca 19"

1

Rossini, Rosaria, Silvestro Poccia, K. Selcuk Candan, and Maria Luisa Sapino. "CA-Smooth." In MEDES '19: 11th International Conference on Management of Digital EcoSystems. New York, NY, USA: ACM, 2019. http://dx.doi.org/10.1145/3297662.3365830.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Thomas, Dhanya S., Ajit Sebastian, Vinotha Thomas, Anitha Thomas, Rachel Chandy, and Abraham Peedicayil. "Role of CA 19-9 in complex ovarian tumors." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685299.

Full text
Abstract:
Background: Cancer antigen 19-9 (CA 19-9) is a tumor-associated mucin glycoprotein antigen that may be elevated in healthy individuals as well as in patients with benign and malignant tumors. It is useful in the management of pancreatic and other gastrointestinal tumors. CA 19-9 is also elevated in benign and malignant ovarian tumors. Aim: To study the pattern of serum CA19-9 in complex ovarian tumors. Methods: The study design was descriptive, based on data collected from medical records. Patients with a complex ovarian mass, who were investigated with CA 19-9 and had undergone surgery, wereincluded in the study. The study duration was 2 years from January 2014 to December 2015. A total of 273 patients (119 - benign and 154 malignant) with complex ovarian mass and elevated CA 19-9 underwent surgery during the study period. Results: CA 19-9 was elevated in 55 patients (20%). Of these, 23 patients had benign tumors while 32 had malignant tumors.Among patients with benign tumors, 21 had dermoid, 23 had mucinous tumors and 75 had other types of tumors. CA 19-9 was elevated in 10 (47.6%) of the dermoids, 7 (30.4%) of the mucinous tumors and 6 (8%) of the other benign tumors. Among patients with malignant tumors, 138 were epithelial and 16 were non epithelial tumors. Of the epithelial tumors, 31 were mucinous and 107 were non mucinous types. Overall, 29 (21%) had elevated CA 19-9. Of the epithelial tumors, 22.6% of the mucinous type and 20.6% of the non mucinous type had elevated CA 19-9. Among the non-epithelial tumors, 3 (18.8%) had elevated CA19-9. Conclusion: CA 19-9 is elevated in several conditions but most likely to be raised in dermoid cysts and mucinous tumours. CA19-9 levels need to be interpreted along with clinical and radiological findings.
APA, Harvard, Vancouver, ISO, and other styles
3

Thomas, Dhanya S., Ajit Sebastian, Vinotha Thomas, Anitha Thomas, Rachel Chandy, and Abraham Peedicayil. "Role of cancer antigen 19-9 in complex ovarian tumors." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685315.

Full text
Abstract:
Background: Cancer antigen 19-9 (CA 19-9) is a tumor-associated mucin glycoprotein antigen that may be elevated in healthy individuals as well as in patients with benign and malignant tumors. It is useful in the management of pancreatic and other gastrointestinal tumors. CA 19-9 is also elevated in benign and malignant ovarian tumors. Aim: To study the pattern of serum CA 19-9 in complex ovarian tumors. Methods: The study design was descriptive, based on data collected from medical records. Patients with a complex ovarian mass, who were investigated with CA 19-9 and had undergone surgery, were included in the study. The study duration was 2 years from January 2014 to December 2015. A total of 273 patients (119 benign and 154 malignant) with complex ovarian mass and elevated CA 19-9 underwent surgery during the study period. Results: CA 19-9 was elevated in 55 patients (20%). Of these, 23 patients had benign tumors while 32 had malignant tumors. Among patients with benign tumors, 21 had dermoid, 23 had mucinous tumors and 75 had other types of tumors. CA 19-9 was elevated in 10 (47.6%) of the dermoids, 7 (30.4%) of the mucinous tumors and 6 (8%) of the other benign tumors. Among patients with malignant tumors, 138 were epithelial and 16 were non epithelial tumors. Of the epithelial tumors, 31 were mucinous and 107 were nonmucinous types. Overall, 29 (21%) had elevated CA 19-9. Of the epithelial tumors, 22.6% of the mucinous type and 20.6% of the non mucinous type had elevated CA 19-9. Among the non-epithelial tumors, 3 (18.8%) had elevated CA19-9. Conclusion: CA 19-9 is elevated in several conditions but most likely to be raised in dermoid cysts and mucinous tumours. CA19-9 levels need to be interpreted along with clinical and radiological findings.
APA, Harvard, Vancouver, ISO, and other styles
4

Acton, D. Scott, and Robert C. Smithson. "Solar astronomy with a 19-segment adaptive mirror." In San Diego, '91, San Diego, CA, edited by Mark A. Ealey. SPIE, 1991. http://dx.doi.org/10.1117/12.48803.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pandey, Divya, Neha Pruthi, and Sudha Salhan. "Unusually high serum Ca 19-9 in a benign ovarian tumor." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685327.

Full text
Abstract:
Introduction: Ovarian tumors have a varied spectrum of presentation. Tumors which look malignant clinico-biochemically can ultimately turn out to be benign. Tumor markers help in diagnosing various malignancies. Carbohydrate antigen 19-9 is one such marker seen to be elevated in some ovarian tumors. Case: A 55 year old, lean and thin postmenopausal female presented to Gynae OPD with abdominal mass, anorexia and weight loss developing over last 6 months. During workup, she was found to have unusually high Ca 19-9 along with MRI findings suggestive of ovarian tumor. Staging laparotomy followed by total abdominal hysterectomy with bilateral salpingoophorectomy was performed. Per operative findings were suggestive of benign nature of ovarian tumor of size 18× 20 cm. Patient was kept under follow up. Histopathology report showed benign mucinous cystadenoma. The serum levels of Ca19-9 returned to normal 8 weeks following surgery. This case report shows a rare and significant elevation of Ca19-9 levels with benign mucinous cystadenoma of the ovary, thus showing that women with unusually elevated tumor markers and even symptoms suggesting malignancy may actually harbour a benign disease. Conclusion: Unusually high Ca 19-9 may be associated with benign mucinous cystadenoma but thorough workup to rule out malignancy is a must in every case.
APA, Harvard, Vancouver, ISO, and other styles
6

Patel, S., and F. Patel. "COVID-19: An Asymptomatic Carrier." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4114.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Patel, S., V. D. Villgran, and M. Young. "COVID-19: The Great Masquerader." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4099.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Geriani, D., and J. Egan. "Comparison of Tracheostomy Timing and Outcomes Between COVID-19 and Non-COVID-19 Patients." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1762.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hassan, A., H. Salat, A. Ahmed, and T. Khan. "Euglycemic Diabetic Ketoacidosis, SGLT-2 Inhibitors and COVID-19; The Murphy Law of COVID-19." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2448.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Badami, V., B. Hackett, S. Sharma, and R. C. Stansbury. "Sleep Quality After COVID-19 Infection." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1477.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Ca 19"

1

Pillsbury, Norman H., Jared Verner, and William D. Tietje. Proceedings of a symposium on oak woodlands: ecology, management, and urban interface issues; 19–22 March 1996; San Luis Obispo, CA. Albany, CA: U.S. Department of Agriculture, Forest Service, Pacific Southwest Research Station, 1997. http://dx.doi.org/10.2737/psw-gtr-160.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Walshire, Lucas, and Joseph Dunbar. Geotechnical inspection and technical review of Santa Margarita River Marine Corps Air Station Levee, U.S. Marine Corps, Camp Pendleton, CA, 19-20 November 2019. Engineer Research and Development Center (U.S.), August 2021. http://dx.doi.org/10.21079/11681/41526.

Full text
Abstract:
This report describes activities performed, results obtained, and conclusions made from an independent technical review of past levee inspections and the proposed remediation plan for the Santa Margarita Levee that surrounds the U.S. Marine Corps Air Station (MCAS) Camp Pendleton. In support of the technical review, ERDC personnel performed a supplemental levee inspection on 19 and 20 November 2019 with MCAS personnel. Previous levee inspections had rated the levee system as Unacceptable due to unwanted vegetation encroaching on the levee right-of-way, which prevents full inspection during flooding. Concerns were raised by the U.S. Fish and Wildlife (USFW) about environmental impacts of the proposed remediation measures and the necessity of such actions. USFW personnel requested an engineering review from an independent party, and ERDC was tasked with performing the independent technical review. The following special report describes the tasks performed and results obtained from the independent technical review.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Ca 19' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography